Validation of UK Protocols to Exclude Brain Blood Flow During Normothermic Regional Perfusion (NRP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Antonio Rubino
- Phone Number: 01223 639574
- Email: a.rubino@nhs.net
Study Contact Backup
- Name: Thomas Howlett
- Email: thomas.howlett@nhs.net
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- DCD donors in Cambridge University Hospital
- Planned A-NRP
- Consent for study has been obtained
- Those who meet the appropriate criteria for DCD donation following WOLST
- ≥ 18 years of age
- ≤ 75 years of age
Exclusion Criteria:
- DBD organ donors
- DCD organ donations outside of Cambridge University Hospital
- DCD donors without planned A-NRP
- DCD donors whose family have withheld consent for brain blood flow investigations.
- Patients who do not meet the appropriate criteria for DCD donation following WOLST
- Patients with injuries that will physically prevent use of the necessary assessment methods
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
A-NRP
|
CT angiography of the brain 30 minutes from establishment of NRP
|
|
TA-NRP
|
CT angiography of the brain 30 minutes from establishment of NRP
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CT angiogram
Time Frame: 30 minutes from establishment of NRP
|
Brain blood flow
|
30 minutes from establishment of NRP
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cerebral oximetry
Time Frame: Prior to withdrawal of life sustaining treatment to 30 minutes after establishment of NRP
|
HbO2 measurements (O2Hbi (Delta oxygenated), HHbi (Delta deoxygenated), and cHbi (Delta total))
|
Prior to withdrawal of life sustaining treatment to 30 minutes after establishment of NRP
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PO3027
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.